 |
|
Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab
Jeffrey M. Weinberg, MD;
Elaine C. Siegfried, MD
Departments of Dermatology, St Luke’s-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY (Dr Weinberg); Department of Dermatology, Saint Louis University, St Louis, Mo (Dr Siegfried)
Arch Dermatol. 2006;142:555-558.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
REPORT OF CASES
CASE 1
An 8-year-old white boy presented in January 2003 with a long-standing history of atopic dermatitis, with onset between ages 1 and 2 years, in addition to insulin-dependent diabetes mellitus diagnosed at age 7 years. During the prior 6 years, he had undergone treatment with a variety of topical corticosteroids, 1% pimecrolimus cream, emollients, and courses of prednisone. Both diseases were poorly controlled.
The patient was initially treated with 0.05% diflorasone diacetate ointment, petroleum jelly, and oral cetirizine. In February 2003, 4 mg/kg per day of oral cyclosporine was added to his regimen. This was subsequently increased to 5.6 mg/kg per day in late March and to 6.2 mg/kg per day in late April. In March and May 2003, he received 2 courses of oral cephalexin for flares.
In June 2003, UV-B therapy was added 3 times weekly. The patient showed improvement over . . . [Full Text of this Article] CASE 2
THERAPEUTIC CHALLENGE
SOLUTION
COMMENT
AUTHOR INFORMATION
RELATED LETTER
Rebound Vasodilation From Long-term Topical Corticosteroid Use
Marvin Rapaport
Arch Dermatol. 2007;143(2):268-269.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Development of Atopic Dermatitis During the First 3 Years of Life: The Copenhagen Prospective Study on Asthma in Childhood Cohort Study in High-Risk Children
Liselotte Brydensholt Halkjær, Lotte Loland, Frederik F. Buchvald, Tove Agner, Lone Skov, Matthew Strand, and Hans Bisgaard
Arch Dermatol. 2006;142(5):561-566.
ABSTRACT
| FULL TEXT
Topical Calcineurin Inhibitors for Atopic Dermatitis: Balancing Clinical Benefit and Possible Risks
Abrar A. Qureshi and Michael A. Fischer
Arch Dermatol. 2006;142(5):633-637.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Combination Immunosuppressive Therapies: The Promise and the Peril
Robinson et al.
Arch Dermatol 2007;143:1053-1057.
ABSTRACT
| FULL TEXT
Efalizumab in the Treatment of Discoid Lupus Erythematosus
Usmani and Goodfield
Arch Dermatol 2007;143:873-877.
ABSTRACT
| FULL TEXT
Rebound Vasodilation From Long-term Topical Corticosteroid Use
Rapaport
Arch Dermatol 2007;143:268-269.
FULL TEXT
|
